CCL22-specific T Cells: Modulating the immunosuppressive tumor microenvironment

ABSTRACT Tumor cells and tumor-infiltrating macrophages produce the chemokine CCL22, which attracts regulatory T cells (Tregs) into the tumor microenvironment, decreasing anticancer immunity. Here, we investigated the possibility of targeting CCL22-expressing cells by activating specific T cells. We analyzed the CCL22 protein signal sequence, identifying a human leukocyte antigen A2- (HLA-A2-) restricted peptide epitope, which we then used to stimulate peripheral blood mononuclear cells (PMBCs) to expand populations of CCL22-specific T cells in vitro. T cells recognizing an epitope derived from the signal-peptide of CCL22 will recognize CCL22-expressing cells even though CCL22 is secreted out of the cell. CCL22-specific T cells recognized and killed CCL22-expressing cancer cells. Furthermore, CCL22-specific T cells lysed acute monocytic leukemia cells in a CCL22 expression-dependent manner. Using the Enzyme-Linked ImmunoSPOT assay, we examined peripheral blood mononuclear cells from HLA-A2+ cancer patients and healthy volunteers for reactivity against the CCL22-derived T-cell epitope. This revealed spontaneous T-cell responses against the CCL22-derived epitope in cancer patients and in healthy donors. Finally, we performed tetramer enrichment/depletion experiments to examine the impact of HLA-A2-restricted CCL22-specific T cells on CCL22 levels among PMBCs. The addition or activation of CCL22-specific T cells decreased the CCL22 level in the microenvironment. Activating CCL22-specific T cells (e.g., by vaccination) may directly target cancer cells and tumor-associated macrophages, thereby modulating Treg recruitment into the tumor environment and augmenting anticancer immunity.

[1]  M. Andersen.  Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy. , 2015, Journal of the National Cancer Institute.

[2]  K. Kelsey,et al.  Serum macrophage‐derived chemokine/CCL22 levels are associated with glioma risk, CD4 T cell lymphopenia and survival time , 2015, International journal of cancer.

[3]  Mark M. Davis,et al.  Clonal Deletion Prunes but Does Not Eliminate Self-Specific αβ CD8(+) T Lymphocytes. , 2015, Immunity.

[4]  Xiang Hu,et al.  The role of the CCL22-CCR4 axis in the metastasis of gastric cancer cells into omental milky spots , 2014, Journal of Translational Medicine.

[5]  M. Andersen,et al.  The targeting of immunosuppressive mechanisms in hematological malignancies , 2014, Leukemia.

[6]  M. Donia,et al.  HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients. , 2013, Cancer research.

[7]  J. Blay,et al.  Innate immune recognition of breast tumor cells mediates CCL22 secretion favoring Treg recruitment within tumor environment , 2012, Oncoimmunology.

[8]  Hiroaki Tanaka,et al.  Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival , 2012, Nature Medicine.

[9]  D. Hanahan,et al.  A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. , 2011, Blood.

[10]  J. Blay,et al.  Early detection of tumor cells by innate immune cells leads to T(reg) recruitment through CCL22 production by tumor cells. , 2011, Cancer research.

[11]  J. Blay,et al.  Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. , 2009, Cancer research.

[12]  M. Colombo,et al.  Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy , 2007, Nature Reviews Cancer.

[13]  S. Iida,et al.  Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. , 2006, Cancer research.

[14]  T. Schumacher,et al.  Design and use of conditional MHC class I ligands , 2006, Nature Medicine.

[15]  E. Gilboa,et al.  Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. , 2005, The Journal of clinical investigation.

[16]  Youjin Lee,et al.  Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors , 2005, The Journal of experimental medicine.

[17]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[18]  Yao-Tseng Chen,et al.  Cross-Presentation of HLA Class I Epitopes from Exogenous NY-ESO-1 Polypeptides by Nonprofessional APCs 1 , 2003, The Journal of Immunology.

[19]  A. Iellem,et al.  Unique Chemotactic Response Profile and Specific Expression of Chemokine Receptors Ccr4 and Ccr8 by Cd4+Cd25+ Regulatory T Cells , 2001, The Journal of experimental medicine.

[20]  C. Huber,et al.  Transporter (TAP)‐ and proteasome‐independent presentation of a melanoma‐associated tyrosinase epitope , 2000, International journal of cancer.

[21]  T. Elliott,et al.  Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL. , 1999, Journal of immunology.

[22]  R. Henderson,et al.  HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. , 1992, Science.

[23]  H. Flyger,et al.  High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer , 2010, Breast Cancer Research and Treatment.